Henry Schein (NASDAQ:HSIC) Issues Earnings Results

Henry Schein (NASDAQ:HSIC) posted its earnings results on Tuesday. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05, Briefing.com reports. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The company’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm earned $1.32 earnings per share. Henry Schein updated its FY 2024 guidance to 4.740-4.820 EPS.

Henry Schein Stock Down 0.4 %

Henry Schein stock opened at $69.72 on Thursday. Henry Schein has a fifty-two week low of $62.12 and a fifty-two week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. The firm’s 50-day simple moving average is $70.59 and its 200 day simple moving average is $69.78. The stock has a market cap of $8.83 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Baird R W upgraded shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Evercore ISI raised their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Robert W. Baird cut their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. UBS Group cut their price objective on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $77.50.

Insider Buying and Selling at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.